In a syngeneic mouse model, the IL34-enriched TME attracted more monocyte-derived tumor-associated macrophages (MD-TAMs), which negatively altered tumor immunity and vasculature, the two protumor features targeted by current RCC therapy. Here, IL34 is linked to neoplasm.